


Ask a doctor about a prescription for LIDOCAINE/EPINEPHRINE NORMON 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION
LEAFLET: INFORMATION FOR THE USER
Lidocaine/Epinephrine Normon 20 mg/ml + 0.0125 mg/ml injectable solution EFG
Lidocaine hydrochloride monohydrate/Epinephrine (bitartrate)
Read the entire leaflet carefully before starting to use this medicine, as it contains important information for you.
Contents of the leaflet:
Lidocaine/Epinephrine Normon 20 mg/ml + 0.0125 mg/ml is indicated for local dental anesthesia, by infiltration or trunk block.
Do not use Lidocaine/Epinephrine Normon:
Warnings and precautions
Avoid injection into an inflamed or infected area.
Consult your doctor, even if any of the above circumstances have occurred to you in the past.
Tell your doctor or pharmacist if you are taking or have recently taken any other medicine, including those obtained without a prescription. Some medicines may influence the action of others.
It is not recommended to administer Lidocaine/Epinephrine Normon with the following medicines:
Intramuscular injection of lidocaine may increase phosphokinase levels.
After administration of Lidocaine/Epinephrine Normon, do not eat until sensitivity has been restored.
Consult your doctor or pharmacist before using any medicine. Special caution should be exercised when prescribing to pregnant women.
Lidocaine is excreted in small amounts in breast milk. No problems have been described during breastfeeding.
Driving and using machines:Although no effects on the ability to drive are expected, the dentist will decide when you are able to drive and operate machinery.
This medicine may cause severe allergic reactions and bronchospasm (sudden feeling of suffocation) because it contains sodium metabisulfite (E-223).
For doses below 3.91 ml, this medicine contains less than 23 mg of sodium per dose; i.e., it is essentially "sodium-free".
For doses equal to or greater than 3.91 ml, this medicine contains 23 or more mg of sodium (main component of table/cooking salt) in each dose equivalent to 1.1-7.3% of the maximum recommended daily sodium intake for an adult.
Athletes are informed that this medicine contains a component that may result in a positive doping test.
Your dentist will determine the dose and method of administration of Lidocaine/Epinephrine Normon.
If you think the action of this medicine is too strong or too weak, tell your doctor or pharmacist.
In infiltrations or terminal anesthesia, it is generally sufficient to administer 1 ml of Lidocaine/Epinephrine Normon. In trunk anesthesia, the dose will be 1.5 to 2 ml. The maximum dose in 24 hours is 500 mg of lidocaine, and it should not exceed 7 mg/kg of body weight in adults.
Do not eat until sensitivity has been restored.
Pediatric population and special populations
In children, elderly patients, debilitated patients, and patients with cardiac and/or hepatic diseases, the doses should be reduced, according to age and physical condition.
Method of administration
Administration should be done slowly.
Do not administer intravenously.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or nurse immediately, or call the Toxicology Information Service, phone 91-562 04 20, indicating the medicine and the amount used.
Respiratory, circulatory, and convulsive complications may occur. If they occur, administration will be interrupted, and appropriate treatment will be initiated.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, Lidocaine/Epinephrine Normon can have side effects, although not everyone will experience them.
The frequencies of adverse reactions are defined as: very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), rare (may affect up to 1 in 1,000 people), very rare (may affect up to 1 in 10,000 people), and frequency not known (cannot be estimated from available data).
Very common (at least 1 in 10 patients):excitement, agitation, dizziness, tinnitus (ringing in the ears), blurred vision, nausea, vomiting, tremors, and convulsions. After excitement, respiratory depression and coma may appear, even with myocardial depression (decreased heart muscle activity), hypotension (decreased blood pressure), bradycardia (slow heart rate), arrhythmia (alterations in heart rhythm and frequency), and cardiac arrest.
Very rare(less than 1 in 10,000 patients):Allergic reactions.
Other adverse reactions:Epinephrine may cause tachycardia (rapid heart rate), cardiac rhythm disorders, increased blood pressure, although it is extremely rare.
If you think any of the side effects you are experiencing is serious, or if you notice any side effect not mentioned in this leaflet, tell your doctor or pharmacist.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist or nurse, even if it is a possible side effect not listed in this leaflet.
You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of sight and reach of children.
Do not store above 30°C and keep in the original packaging to protect from light. Do not freeze.
Expiry date:Do not use Lidocaine/Epinephrine Normon after the expiry date stated on the packaging, after the expiry date. The expiry date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Lidocaine/Epinephrine Normon 20 mg/ml + 0.0125 mg/ml injectable solution EFG
The active ingredients are Lidocaine hydrochloride monohydrate and Epinephrine (bitartrate). Each ml of the solution contains: Lidocaine hydrochloride monohydrate and Epinephrine (bitartrate).
The other ingredients are: Sodium metabisulfite (E-223), sodium chloride, water for injectable preparations.
Appearance of the product and package contents
Lidocaine/Epinephrine Normon 20 mg/ml + 0.0125 mg/ml:clear, colorless or slightly yellowish solution.
Lidocaine/Epinephrine Normon 20 mg/ml + 0.0125 mg/ml is an injectable solution. It is presented in cartridges, in packages containing 1 cartridge of 1.7 ml and a leaflet.
Marketing authorization holder and manufacturer
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN)
This leaflet was last revised in February 2020
Other sources of information
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
This information is intended only for healthcare professionals
For injection into the oral mucosa.
FOR USE ONLY IN DENTAL ANESTHESIA.
To avoid intravenous injection, aspiration should always be performed before injection.
The use of the appropriate injection syringe for infiltration anesthesia ensures perfect functioning, as well as maximum safety against cartridge breakage. Only the contents of intact cartridges should be injected.
In order to avoid any risk of infection (e.g., prevention of hepatitis transmission), it is essential to use newly sterilized syringes and needles. The remaining contents of partially used cartridges should not be administered to other patients.
For external disinfection of the cartridges, 91% isopropyl alcohol or 70% ethanol without denaturants is recommended. Solutions containing heavy metals are not recommended, as they release ions (mercury, zinc, copper, etc.), which can cause edema in local dental anesthetics.
When using any local anesthetic, oxygen, equipment, and resuscitation medications should be available.
Like other local anesthetics, due to excessive dosing, rapid absorption, or unnoticed intravascular injection, symptoms of intoxication may occur in the form of respiratory, circulatory, and convulsive complications.
In these cases, for respiratory disorders, ensure and maintain an open airway, administer oxygen, and initiate controlled or assisted breathing if necessary. In some patients, endotracheal intubation may be necessary.
For circulatory depression, it is recommended to administer a vasoconstrictor (preferably ephedrine) and intravenous fluids.
For convulsive crises, if the convulsions do not respond to assisted breathing, it is recommended to administer a benzodiazepine such as diazepam (in increments of 2.5 mg) or an ultrashort-acting barbiturate, such as thiopental or thiamylal (in increments of 50 to 100 mg) intravenously every 2 or 3 minutes. It should be kept in mind that in these circumstances, especially barbiturates, may cause circulatory depression when administered intravenously. It is also recommended to administer a neuromuscular blocker to reduce the muscular manifestations of persistent convulsive crises. When these drugs are administered, artificial respiration is mandatory.
Injection into an inflamed area should be avoided.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LIDOCAINE/EPINEPHRINE NORMON 20 mg/mL + 0.0125 mg/mL INJECTABLE SOLUTION – subject to medical assessment and local rules.